Norepinephrine Drug Market

Segmentation By Product (Oral Medication and Intravenous Therapy); By Application (Neurogenic Shock, Septic Shock, and Others); By End-User (Hospitals, Private Clinics, Ambulatory Surgery Centres, and Others) – Global Demand Analysis & Opportunity Outlook 2028

Buy Now
Report ID: 2532 | Published On: Feb 07, 2023
Request Free Sample Copy

Growth Drivers

Exceptional properties of norepinephrine drug

Norepinephrine drug has some exceptional advantages over other alpha-adrenergic agonists, it is considered to have more predictive pharmaceutical properties. This predictive quality, combined with some of its beta-adrenergic agonist (which improves cardiac function comparative to pure alpha-adrenergic agonists), makes norepinephrine a widely used sympathomimetic drug. It is commonly used in intensive care units to treat hypotension. Additionally, it is the first-line agent for treating hypotension. This advantage is anticipated to provide lucrative business opportunities for norepinephrine drugs market during the forecast period. 

Surge in geriatric individuals to boost the norepinephrine drug market

According to a 2017 UN report on World Population Ageing, the global population aged 60 years or over totalled 962 million in 2017, more than twice as large as in 1980 when there were 382 million older persons worldwide. The number of geriatric individuals is expected to double again by 2050 when it is projected to reach nearly 2.1 billion.

Aged individuals are more prone to the risk of low blood pressure, and at present, the population of geriatric individuals in most of the developed economies along with developing nations is increasing at a significant rate. The risk of hypotension normally increases with age due to the decline in blood flow to the heart, muscle and the brain, which often result in the plaque build-up in blood vessels. Hence, the rise in geriatric population is estimated to contribute towards the market demand for norepinephrine drug in future.

Get more information on this report: Request Sample PDF

Market Size and Forecast

The norepinephrine drug market is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. In 2020, the market is growing at a stable rate owing to the rising prevalence of low blood pressure condition globally, along with the improved efficacy and predictive pharmacological properties of norepinephrine drug. On the other hand, the rapidly increasing geriatric population is driving the market growth further. The norepinephrine drug market is segmented by product, by application, by end-user, and by region. Based on the end-user, the norepinephrine market is segmented into hospitals, private clinics, ambulatory surgery centers, and others, out of which, the hospital segment accounts for the largest market share on account of the increase in the number of elderly patients every year. Elderly in-patients are higher than the patients in-home care settings owing to the intensive monitoring and caring routine of elderly patients at hospitals. Norepinephrine is a strong drug and excellent at increasing systematic vascular resistance therefore, it is globally used as first-line agents to treat hypotension in patients with acute circulatory failure. Norepinephrine is considered to be better than dopamine owing to its properties and fewer adverse side-effects. All these factors are expected to thrive in the norepinephrine market in the coming years.


Side Effects of Drug to Hamper the Market Growth

Drugs are given to save patients from life-threatening conditions and are used to deliver viability to serious condition patients. Except that there are a few major side effects associated with the norepinephrine drug present in the market. These might consist of sudden numbness, weakness, uneven heart rate, blue lips or fingernails, mottled skin, trouble breathing, problem with speech, severe headache, blurred vision and others. Moreover, stopping the norepinephrine drug might lead to the recurrence of low blood pressure (hypotension). On account of these, the market for the norepinephrine drugs is estimated to observe limited growth in future.

Market Segmentation

In-depth analysis of the global norepinephrine drug market includes the following segments:

By Product Type:

  • Oral Medication
  • Intravenous Therapy

By Application Type:

  • Neurogenic shock
  • Septic Shock
  • Others

By End-User Type:

  • Hospitals
  • Private Clinics
  • Ambulatory surgery centres
  • Others

By Region Type

On the basis of regional analysis, the global norepinephrine drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Based on the region, the markets in North America and Europe are anticipated to hold significantly large market shares owing to the rising geriatric population in these developed nations. Additionally, the early adoption of cutting edge technology and innovations along with the considerable presence of the key market player in the region are further estimated to boost the market growth. On the other hand, norepinephrine market in Asia-Pacific region is likely to show an upward growth in the years to come. This can be accredited to the rising population of geriatric people in the region.


The global norepinephrine drug market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Market

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample